REGENXBIO Announces FDA Clearance of IND for Clinical Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy
- Thursday, January 6, 2022, 7:13
- Environment
- Add a comment
ROCKVILLE, Md., Jan. 6, 2022 /PRNewswire/ — Potential one-time gene therapy for the treatment of Duchenne includes a novel, optimized microdystrophin transgene and REGENXBIO’s proprietary NAV® AAV8 vector Innovative trial design, including comprehensive immunosuppressive regimen, to…
About the Author
adminasapcorp has written 41538 stories on this site.